Clouding of consciousness

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Retrieved on: 
tisdag, mars 26, 2024
Brain, Disease, Somnolence, Appetite, Partnership, Headache, Visual analogue scale, Patient, Insomnia, EDS, Anxiety, SDX, Doctor of Philosophy, Epworth Sleepiness Scale, Nausea, Clinical trial, Therapy, Safety, Narcolepsy, ESS, IHSS, Idiopathic hypersomnia, Clouding of consciousness, BFS, Food, Pharmaceutical industry

CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). This proof-of-concept study was not powered to demonstrate statistical significance.   The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.

Key Points: 
  • CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial ( NCT05668754 ) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).
  • The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.
  • The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.
  • The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.

RAIsonance Releases New Fall 2023 Workforce Risk Forecast

Retrieved on: 
tisdag, augusti 22, 2023
Sentinel, Bureau of Labor Statistics, Workforce, Clouding of consciousness, Presenteeism, COPD, Asthma, LC, Health, SARS-CoV-2, Parent, Infection, COVID-19, Risk management, Charles Raison, COVID, Harvard Business Review, CDC, Incidence, RSV, Absenteeism, Brain, Mining, Korea Disease Control and Prevention Agency, Adenoviridae, Morale, Environment, Disease, Construction, Pharmaceutical industry, Vaccine, Omicron

GREENWOOD VILLAGE, Colo., Aug. 22, 2023 /PRNewswire/ -- RAIsonance today announced the release of its Fall 2023 Workforce Wellness Risk Forecast Report.

Key Points: 
  • GREENWOOD VILLAGE, Colo., Aug. 22, 2023 /PRNewswire/ -- RAIsonance today announced the release of its Fall 2023 Workforce Wellness Risk Forecast Report.
  • This specialized forecast delivers comprehensive insights into rising health risks likely to affect workforce health and productivity this fall, across industries and sectors.
  • The Fall 2023 report cites several specific trends that could create a very challenging environment for employers through the remainder of 2023.
  • "To support our enterprise clients, we watch these increasing workforce wellness threat indicators very closely," said Kris Hopkins, Chief Product Officer at RAIsonance.

Revitalist Executes LOI to Enter into a Clinical Research Collaboration with MYND

Retrieved on: 
tisdag, november 9, 2021
Health, Managed Care, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MD, CSE, Clinical trial, FSE, CEO, Brain, World, World Health Organization, Lists of diseases, Food, COVID-19, Clouding of consciousness, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuro, Interview, Partnership, Vaccine, Mental health, CALM, Diagnosis, MAP, Physician, Wellness, Â, Patient, OTC, FDA, Medical imaging, Pharmaceutical industry, Medical device

REVITALIST LIFESTYLE AND WELLNESS LTD. (Revitalist or the Company) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce it has executed a binding letter of intent (LOI) with MYND DIAGNOSTICS INC., (MYND Diagnostics), a wholly owned subsidiary of MYND LIFE SCIENCES INC. (MYND) (CSE:MYND) (OTC:MYNDF) to enter into a clinical research collaboration studying a link between diagnostic results and improved patient outcomes using MYND Diagnostics proprietary anti-inflammatory peptide (MAP) biomarker.

Key Points: 
  • REVITALIST LIFESTYLE AND WELLNESS LTD. (Revitalist or the Company) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce it has executed a binding letter of intent (LOI) with MYND DIAGNOSTICS INC., (MYND Diagnostics), a wholly owned subsidiary of MYND LIFE SCIENCES INC. (MYND) (CSE:MYND) (OTC:MYNDF) to enter into a clinical research collaboration studying a link between diagnostic results and improved patient outcomes using MYND Diagnostics proprietary anti-inflammatory peptide (MAP) biomarker.
  • Kathryn Walker, CEO of Revitalist stated We are excited to be working with MYND Diagnostics to potentially diagnose and monitor mental health using MAP.
  • MYND is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property.
  • Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness.

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

Retrieved on: 
tisdag, november 9, 2021
The Company, MD, CSE, Clinical trial, FSE, CEO, Brain, World, World Health Organization, Lists of diseases, Food, COVID-19, Clouding of consciousness, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuro, Interview, Vaccine, Mental health, CALM, Company, Diagnosis, MAP, Physician, Wellness, Patient, OTC, FDA, Medical imaging, Pharmaceutical industry, Medical device

VANCOUVER, BC, Nov. 9, 2021 /PRNewswire/ -MYND LIFE SCIENCES INC. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF)is pleased to announceits wholly-owned subsidiary MYND DIAGNOSTICS INC. ("MYND Diagnostics")has executed a binding letter of intent ("LOI") with REVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist") (CSE:CALM) (OTC:RVLWF) (FSE: 4DO) to enter into a clinical research collaboration studying a link between diagnostic results and improved patient outcomes using MYND Diagnostics' proprietary anti-inflammatory peptide ("MAP") biomarker.

Key Points: 
  • VANCOUVER, BC, Nov. 9, 2021 /PRNewswire/ -MYND LIFE SCIENCES INC. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF)is pleased to announceits wholly-owned subsidiary MYND DIAGNOSTICS INC. ("MYND Diagnostics")has executed a binding letter of intent ("LOI") with REVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist") (CSE:CALM) (OTC:RVLWF) (FSE: 4DO) to enter into a clinical research collaboration studying a link between diagnostic results and improved patient outcomes using MYND Diagnostics' proprietary anti-inflammatory peptide ("MAP") biomarker.
  • Kathryn Walker, CEO of Revitalist stated "We are excited to be working with MYND Diagnostics to potentially diagnose and monitor mental health using MAP.
  • Since opening their first clinic in 2018, Revitalist has provided thousands of infusions for patients suffering from treatment-resistant conditions.
  • Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness.